海爾智家(600690.SH):發行不超28.57億股H股獲中證監核准批覆
格隆匯10月30日丨海爾智家(600690.SH)宣佈,2020年10月30日,公司收到中國證監會核發的《關於核准海爾智家股份有限公司發行境外上市外資股及可轉換公司債券的批覆》(證監許可[2020]2768號)。
根據該批覆,中國證監會核准公司發行不超過約28.57億股(含不超過80億港元或等值外幣可轉換公司債券持有人行使轉股權而增發的股份)境外上市外資股,每股面值人民幣1元,全部為普通股,完成該次發行後,公司可到香港聯交所主板上市;核准公司擔保的境外全資下屬公司在境外發行不超過80億港元或等值外幣可轉換為公司境外上市外資股的公司債券。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.